Profile data is unavailable for this security.
About the company
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
- Revenue in USD (TTM)42.34m
- Net income in USD-205.75m
- Incorporated2008
- Employees165.00
- LocationEyePoint Inc480 Pleasant Street, Suite C400WATERTOWN 02472United StatesUSA
- Phone+1 (617) 926-5000
- Fax+1 (617) 926-5050
- Websitehttps://eyepoint.bio/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precigen Inc | 6.31m | -425.87m | 1.19bn | 143.00 | -- | 28.52 | -- | 189.28 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| Collegium Pharmaceutical Inc | 780.57m | 62.87m | 1.27bn | 423.00 | 23.38 | 4.20 | 4.39 | 1.63 | 1.71 | 1.71 | 20.54 | 9.51 | 0.4702 | 8.30 | 3.55 | 1,845,312.00 | 3.79 | 3.89 | 5.30 | 5.96 | 59.35 | 56.32 | 8.05 | 8.34 | 1.48 | 2.65 | 0.7285 | 0.00 | 23.62 | 20.28 | -9.13 | 18.64 | -65.83 | -- |
| Harrow Inc | 250.04m | -4.99m | 1.44bn | 382.00 | -- | 30.41 | 105.05 | 5.75 | -0.1522 | -0.1522 | 6.70 | 1.27 | 0.6998 | 5.53 | 3.81 | 654,560.20 | -1.40 | -9.11 | -1.80 | -10.89 | 74.56 | 72.78 | -1.99 | -14.34 | 2.52 | 1.11 | 0.8388 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
| EyePoint Inc | 42.34m | -205.75m | 1.52bn | 165.00 | -- | 6.37 | -- | 35.82 | -2.99 | -2.99 | 0.617 | 2.88 | 0.1532 | 1.02 | 59.51 | 256,606.10 | -74.47 | -35.88 | -86.87 | -42.05 | 94.08 | 84.82 | -485.95 | -201.78 | 7.11 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Perrigo Company PLC | 4.25bn | -1.40bn | 1.57bn | 8.10k | -- | 0.5339 | -- | 0.3686 | -10.19 | -10.36 | 30.80 | 21.33 | 0.4678 | 2.47 | 6.37 | 525,074.10 | -15.42 | -3.52 | -17.39 | -4.03 | 35.14 | 34.70 | -32.97 | -8.36 | 1.63 | 1.91 | 0.5536 | -- | -2.75 | 0.794 | -772.62 | -- | -14.60 | 5.21 |
| Harmony Biosciences Holdings Inc | 868.45m | 158.69m | 1.64bn | 293.00 | 10.42 | 1.88 | 8.89 | 1.88 | 2.71 | 2.71 | 14.87 | 15.07 | 0.7649 | 31.60 | 9.66 | 2,964,004.00 | 13.98 | 17.23 | 17.21 | 20.92 | 77.16 | 78.84 | 18.27 | 22.32 | 3.58 | -- | 0.1583 | -- | 21.51 | 40.30 | 9.07 | -- | 528.16 | -- |
| Immunocore Holdings PLC - ADR | 400.02m | -35.51m | 1.64bn | 524.00 | -- | 4.30 | -- | 4.10 | -0.7057 | -0.7057 | 7.87 | 7.52 | 0.3852 | 0.8348 | 5.84 | 763,389.30 | -3.42 | -11.69 | -4.39 | -14.93 | 98.73 | -- | -8.88 | -32.06 | 4.01 | -- | 0.5078 | -- | 28.95 | 59.62 | 30.48 | -- | 1.95 | -- |
| Innoviva Inc | 411.33m | 271.17m | 1.65bn | 159.00 | 7.20 | 1.42 | 5.30 | 4.02 | 3.10 | 3.10 | 5.18 | 15.71 | 0.2802 | 2.84 | 4.58 | 2,586,969.00 | 18.47 | 17.66 | 20.46 | 19.58 | 74.80 | -- | 65.92 | 58.96 | 13.85 | -- | 0.1802 | -- | 14.67 | 4.08 | 1,059.22 | 3.86 | 281.45 | -- |
| Sarepta Therapeutics Inc | 2.20bn | -713.41m | 1.67bn | 835.00 | -- | 1.46 | -- | 0.7578 | -7.20 | -7.20 | 21.50 | 10.87 | 0.6012 | 0.8101 | 4.40 | 2,632,619.00 | -19.51 | -12.81 | -26.01 | -15.87 | 69.33 | 80.21 | -32.45 | -30.61 | 1.48 | -21.14 | 0.4209 | -- | 15.58 | 32.41 | -403.27 | -- | 5.09 | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.68bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 883.37m | 70.21m | 1.71bn | 970.00 | 22.85 | 3.17 | 10.12 | 1.93 | 3.33 | 3.33 | 42.25 | 24.03 | 0.6484 | 2.44 | 3.51 | 910,686.60 | 5.75 | -0.2549 | 6.96 | -0.3002 | 61.36 | 59.78 | 8.87 | -0.473 | 2.19 | 6.52 | 0.533 | -- | 43.78 | 33.48 | 448.52 | -- | 17.66 | -- |
| Vericel Corp | 276.26m | 16.52m | 1.75bn | 398.00 | 130.61 | 4.91 | 61.89 | 6.32 | 0.2633 | 0.2633 | 5.26 | 7.01 | 0.6001 | 4.05 | 3.78 | 694,118.10 | 3.59 | -0.0292 | 4.02 | -0.0331 | 74.42 | 70.68 | 5.98 | -0.0467 | 4.68 | -- | 0.0056 | -- | 16.45 | 17.34 | 59.41 | 41.97 | 59.56 | -- |
| Organon & Co | 6.22bn | 187.00m | 1.80bn | 10.00k | 9.63 | 2.39 | 3.28 | 0.289 | 0.7166 | 0.7166 | 23.86 | 2.89 | 0.4787 | 2.13 | 4.62 | 621,600.00 | 1.44 | 7.45 | 1.79 | 9.65 | 53.30 | 59.42 | 3.01 | 13.85 | 1.23 | 2.62 | 0.92 | 25.68 | -2.92 | -0.9868 | -78.36 | -39.23 | 4.38 | -- |
| Aurinia Pharmaceuticals Inc | 283.06m | 287.20m | 1.88bn | 300.00 | 6.80 | 3.22 | 6.14 | 6.65 | 2.08 | 2.08 | 2.04 | 4.39 | 0.4347 | 0.7693 | 7.26 | -- | 44.11 | -2.73 | 51.71 | -3.10 | 88.46 | 90.63 | 101.47 | -8.50 | 4.76 | -- | 0.1059 | -- | 20.38 | 41.38 | 4,893.08 | -- | -49.05 | -- |
Data as of Mar 04 2026. Currency figures normalised to EyePoint Inc's reporting currency: US Dollar USD
59.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cormorant Asset Management LPas of 31 Dec 2025 | 8.27m | 9.98% |
| Suvretta Capital Management LLCas of 31 Dec 2025 | 7.83m | 9.46% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 5.43m | 6.56% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 4.98m | 6.01% |
| Federated Global Investment Management Corp.as of 31 Dec 2025 | 4.81m | 5.81% |
| Adage Capital Management LPas of 31 Dec 2025 | 4.70m | 5.68% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.29m | 5.18% |
| Paradigm BioCapital Advisors LPas of 17 Feb 2026 | 4.19m | 5.06% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 2.94m | 3.55% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.90m | 2.29% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
